New Medicine - A Comprehensive Information and Consulting Service  
HOME PRODUCTS & SERVICES ORDER/INQUIRY PRESS RELEASES EMPLOYMENT CONTACT US

Future Oncology - Technology, Products, Markets, and Service Opportunities

* Requires Adobe Acrobat Reader

FUTURE ONCOLOGY - TECHNOLOGY, PRODUCTS, MARKETS, AND SERVICE OPPORTUNITIES IN THE CANCER FIELD

FUTURE ONCOLOGY
Volume 9 #7/8
AUGUST 31, 2008

DRUG DEVELOPMENT IN ONCOLOGY

THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFr) PATHWAY IN CANCER
PART V - CLINICAL TRIALS OF COMBINATIONS OF APROVED ERBB-PATHWAY INHIBITORS WITH NOVEL AGENTS

EXPLORING AND EXPLOITING THE COMPLEXITIES OF IN VIVO SIGNALING IN THE MODULATION OF THE ERBB PATHWAY

  • Molecular Targets/Pathways
    • A disintegrin and metalloprotease (ADAM) family
    • Akt/protein kinase B (PKB)
    • BIM
    • CXCL12 and CXCR4
    • Cyclin-dependent kinases (CDK)
    • Cyclooxygenase-2 (COX-2)
    • Fibroblast growth factor receptor 1 (FGFr1)
    • Growth factor receptor binding protein 2 (Grb2)
    • Heat shock protein 90 (Hsp90)
    • Histone deacetylases (HDAC)
    • Insulin-like growth factor 1 receptor (IGF1r)
    • Integrin α2 (ITGA2)
    • Kras
    • Mammalian target of rapamycin (mTOR)
    • Met/hepatocyte growth factor receptor (HGFr)
    • MicroRNA-7
    • PC cell-derived growth factor (PCDGF/GP88)
    • Periostin
    • Phosphatidylinositide 3-kinases (PI3K)
    • Platelet-derived growth factor receptor (PDGFr)
    • Proteasome
    • Toll-like receptors (TLr)
    • Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)
    • Vascular endothelial growth factors (VEGF) and their receptors
    • WW domain-containing oxidoreductase (Wwox)

CLINICAL TRIALS OF COMBINATIONS OF APPROVED ERBB-PATHWAY INHIBITORS WITH NOVEL AGENTS

ERBITUX COMBINATIONS

  • Solid tumors
    • Everolimus
  • Colorectal Cancer and Other Gastrointestinal Malignancies
    • 1018 ISS
    • Apo2L/TRAIL
    • Apomab
    • Brivanib
    • E7820
    • Enzastaurin
    • Everolimus
    • IMC-A12
    • IMOxine
    • Imprime PGG
    • MK-0646
    • Pazopanib
    • Pertuzumab
    • Vandetanib
  • Head and Neck Cancer
    • IMC-A12

VECTIBIX COMBINATIONS

  • Colorectal Cancer
    • AMG-655
    • AMG-706
  • Non-small Cell Lung Cancer
    • AMG-706

TARCEVA COMBINATIONS

  • Solid Tumors
    • ARQ 197
    • MP470
    • Pazopanib
    • Tipifarnib
  • Non-small Cell Lung Cancer
    • Apzicoxib
    • ARQ 197
    • CHR-2797
    • CP-751,871
    • Enzastaurin
    • IMOxine
    • MK-0646
    • Pertuzumab
    • PF-3512676
    • Seliciclib
    • SNDX-275/MS-275
    • Volociximab
    • XL184
  • Pancreatic Cancer
    • Apricoxib
    • Asentar
    • Everolimus
  • Breast Cancer
    • Everolimus

IRESSA COMBINATIONS

  • Solid Tumors
    • Cediranib
  • Non-small Cell Lung Cancer
    • Cediranib

HERCEPTIN COMBINATIONS

  • Breast Cancer
    • Alvocidib
    • CNF2024
    • Deforolimus
    • INCB7839
    • Lonafarnib
    • Neratinib
    • Perifosine
    • Pertuzumab
    • Tanespimycin
    • Tipifarnib
    • Vatalanib

TYKERB COMBINATIONS

    • Apricoxib and Lapatinib
    • Pazopanib and Lapatinib


LIST OF EXHIBITS

Exhibit 1 - Targets of Agents Being Evaluated in Combination with ErbB-pathway Inhibitors

Exhibit 2 - Combination Trials of Approved ErbB-pathway Inhibitors with Novel Agents

Exhibit 3 - Global Sales of ErbB-pathway Targeted Agents in 2006/2007

Exhibit 4 - Global Sales of ErbB-pathway Targeted Agents in the First Half of 2008


HOME | PRODUCTS & SERVICES | ORDER/INQUIRY | PRESS RELEASES | EMPLOYMENT | CONTACT US

NEW MEDICINE, INC.
PHONE: 949-830-0448   FAX: 949-830-0887